News

PHI’s Board of Directors proposes a Direct Issue of shares of 9.9 MSEK to Altium

PHI’s Board of Directors proposes a direct issue of 2 374 820 new shares to the Company’s largest shareholder, Altium S.A.
Wake-Forest-North-Carolina

PHI endorses WFIRM as Finalist for NSF’s $160 Million Innovation Grant

PHI proudly stands behind the Wake Forest Institute for Regenerative Medicine (WFIRM) as they contend as a finalist in the National Science Foundation’s (NSF) Regional Innovation Engines competition, with a potential award of up to $160 million.

Notice of Annual General Meeting in Phase Holographic Imaging PHI AB

The shareholders of Phase Holographic Imaging PHI AB (publ), 556542-7811, are hereby invited to the annual general meeting on Friday 27 October 2023 at 13.00 at Scandic Star Hotel, Glimmervägen 5 in Lund.
Green fluorescent cells on a black background.

Interim Report 1 2023/24

During this past summer quarter, we made it our most prosperous Q1 quarter to date, characterized by sustained growth.

Notice that Interim Report 1 2023/24 will be published on September 20, 2023

Phase Holographic Imaging announces that the date for publication of Interim Report 1 2023/24 is September 20, 2023.

PHI AB annual general meeting moved to 27 October 2023

The PHI AB board has decided to move the company’s annual general meeting from 12 October 2023 to 27 October 2023.
Businesspeople brainstorming together with sticky notes in an of

BioStock: PHI links up with two regenerative medicine networks

BioStock contacted CEO Patrik Eschricht to learn more about the company’s future strategies in regenerative medicine and the pivot toward the clinical market.
ARM-ATMP-banner-web

PHI Strengthens Commitment to Regenerative Medicine through ARM and ATMP Sweden Membership

PHI becomes a member of the leading international advocacy organization Alliance for Regenerative Medicine (ARM) as well as the national ATMP Sweden network to advocate for QPI technology for standard cell quality control in regenerative medicine.
BioStock: PHI charts a bold course to impact regenerative medicine

BioStock: PHI charts a bold course to impact regenerative medicine

BioStock contacted CEO Patrik Eschricht to delve into the year-end report’s highlights and shed light on the company’s vision and initiatives.
righst issue of units 2022 banner

BioStock: The five best life science stocks of the first half-year

PHI is proud to be highlighted as one of the top 5 best-performing Swedish life science stocks in the first half of 2023.
1234520